EUVIMEDEUVIMED entdecken
ÄquivalenzstudiePragmatische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCT

Miriam Santer iD, Megan Lawrence iD, Sarah Pyne iD, Susanne Renz iD, Beth L Stuart iD, Tracey Sach iD, Matthew Ridd iD, Kim S Thomas iD, Jacqueline Nuttall iD, Natalia Permyakova iD, Zina Eminton, Nick Francis iD und 6 weitere

Health Technology Assessment · 2024

DOI: 10.3310/myjt6804 ↗

Kurz gefasst

Äquivalenzstudie in der Zeitschrift Health Technology Assessment, 2024. Verfasst von Miriam Santer und 17 weiteren Autor:innen. Beteiligte Einrichtung: Primary Care Research Centre, School of Primary Care, Population Sciences and Medical Education, University of Southampton, Southampton, UK. Hauptthemen laut MEDLINE: Acne Vulgaris, Cost-Benefit Analysis, Quality of Life, Spironolactone. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acne is common, can cause significant impact on quality of life and is a frequent reason for long-term antibiotic use. Spironolactone has been prescribed for acne in women for many years, but robust evidence is lacking.

Objective

To evaluate whether spironolactone is clinically effective and cost-effective in treating acne in women.

Design

Pragmatic, parallel, double-blind, randomised superiority trial.

Setting

Primary and secondary healthcare and community settings (community and social media advertising).

Participants

Women aged 18 years and older with facial acne persisting for at least 6 months, judged to potentially warrant oral antibiotic treatment.

Interventions

Participants were randomised 1 : 1, using an independent web-based procedure, to either 50 mg/day spironolactone or matched placebo until week 6, increasing to 100 mg/day spironolactone or matched placebo until week 24. Participants continued usual topical treatment. Main outcome measures Primary outcome was the adjusted mean difference in Acne-Specific Quality of Life symptom subscale score at 12 weeks. Secondary outcomes included Acne-Specific Quality of Life total and subscales; participant self-assessed improvement; Investigator’s Global Assessment; Participant’s Global Assessment; satisfaction; adverse effects and cost-effectiveness.

Results

Of 1267 women assessed for eligibility, 410 were randomised (201 intervention, 209 control), 342 in the primary analysis (176 intervention, 166 control). Mean age was 29.2 years (standard deviation 7.2) and 7.9% (28/356) were from non-white backgrounds. At baseline, Investigator’s Global Assessment classified acne as mild in 46%, moderate in 40% and severe in 13%. At baseline, 82.9% were using topical treatments. Over 95% of participants in both groups tolerated the treatment and increased their dose. Mean baseline Acne-Specific Quality of Life symptom subscale was 13.0 (standard deviation 4.7) across both groups. Mean scores at week 12 were 19.2 (standard deviation 6.1) for spironolactone and 17.8 (standard deviation 5.6) for placebo [difference favouring spironolactone 1.27 (95% confidence interval 0.07 to 2.46) adjusting for baseline variables]. Mean scores at week 24 were 21.2 (standard deviation 5.9) in spironolactone group and 17.4 (standard deviation 5.8) in placebo group [adjusted difference 3.77 (95% confidence interval 2.50 to 5.03) adjusted]. Secondary outcomes also favoured spironolactone at 12 weeks with greater differences at 24 weeks. Participants taking spironolactone were more likely than those taking placebo to report overall acne improvement at 12 weeks {72.2% vs. 67.9% [adjusted odds ratio 1.16 (95% confidence interval 0.70 to 1.91)]} and at 24 weeks {81.9% vs. 63.3% [adjusted odds ratio 2.72 (95% confidence interval 1.50 to 4.93)]}. Investigator’s Global Assessment was judged successful at week 12 for 31/201 (18.5%) taking spironolactone and 9/209 (5.6%) taking placebo [adjusted odds ratio 5.18 (95% confidence interval 2.18 to 12.28)]. Satisfaction with treatment improved in 70.6% of participants taking spironolactone compared with 43.1% taking placebo [adjusted odds ratio 3.12 (95% confidence interval 1.80 to 5.41)]. Adverse reactions were similar between groups, but headaches were reported more commonly on spironolactone (20.4% vs. 12.0%). No serious adverse reactions were reported. Taking account for missing data through multiple imputation gave an incremental cost per quality-adjusted life-year of £27,879 (adjusted) compared to placebo or £2683 per quality-adjusted life-year compared to oral antibiotics.

Conclusions

Spironolactone resulted in better participant-reported and investigator-reported outcomes than placebo, with greater differences at week 24 than week 12.

Trial registration

This trial is registered as ISRCTN12892056 and EudraCT (2018-003630-33). Funding This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 16/13/02) and is published in full in Health Technology Assessment ; Vol. 28, No. 56. See the NIHR Funding and Awards website for further award information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acne VulgarisCost-Benefit AnalysisQuality of LifeSpironolactoneAdolescentAdultFemaleHumansYoung AdultDouble-Blind MethodMineralocorticoid Receptor AntagonistsQuality-Adjusted Life Years

Stichwörter der Autor:innen

ACNE VULGARISCOST-BENEFIT ANALYSISFEMALEHEALTHCAREHUMANSOUTCOME ASSESSMENTPATIENT-REPORTED OUTCOME MEASURESQUALITY OF LIFERANDOMISED CONTROLLED TRIALSPIRONOLACTONE

Substanzen

Mineralocorticoid Receptor AntagonistsSpironolactone

Autor:innen und Institutionen

  • Primary Care Research Centre, School of Primary Care, Population Sciences and Medical Education, University of Southampton, Southampton, UK.
  • Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
  • Health Economics Group, Norwich Medical School, University of East Anglia, Norwich, UK.
  • Pragmatic Trials Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
  • Population Health Sciences, University of Bristol, Bristol, UK.
  • Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.

ORCID-Profile: Miriam Santer, Megan Lawrence, Sarah Pyne, Susanne Renz, Beth L Stuart, Tracey Sach, Matthew Ridd, Kim S Thomas, Jacqueline Nuttall, Natalia Permyakova, Nick Francis, Paul Little, Ingrid Muller, Irene Soulsby, Karen Thomas, Gareth Griffiths, Alison M Layton

Förderung

  • Health Technology Assessment programme

Zitieren

APA

Santer, M., Lawrence, M., Pyne, S., Renz, S., Stuart, B. L., Sach, T., Ridd, M., Thomas, K. S., Nuttall, J., Permyakova, N., Eminton, Z., Francis, N., Little, P., Muller, I., Soulsby, I., Thomas, K., Griffiths, G., & Layton, A. M. (2024). Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCT. Health Technology Assessment. https://doi.org/10.3310/myjt6804

Vancouver

Santer M, Lawrence M, Pyne S, Renz S, Stuart BL, Sach T, et al. Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCT. Health Technology Assessment. 2024. doi:10.3310/myjt6804

BibTeX
@article{Santer2024,
  author = {Santer, Miriam and Lawrence, Megan and Pyne, Sarah and Renz, Susanne and Stuart, Beth L and Sach, Tracey and Ridd, Matthew and Thomas, Kim S and Nuttall, Jacqueline and Permyakova, Natalia and Eminton, Zina and Francis, Nick and Little, Paul and Muller, Ingrid and Soulsby, Irene and Thomas, Karen and Griffiths, Gareth and Layton, Alison M},
  title = {Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCT},
  journal = {Health Technology Assessment},
  year = {2024},
  doi = {10.3310/myjt6804}
}
Kostenlos starten →